Drug Trial Radar · NCT05201066
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
33
Actual
Start
Feb 28, 2023
Primary completion
Feb 14, 2028
Study completion Feb 14, 2028
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure might offer the unique opportunity to detect rare Adverse Events.
Conditions
- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic
Interventions
decitabineDrug
Solution for intravenous infusion
spartalizumabDrug
Solution for intravenous infusion
sabatolimabDrug
Solution for intravenous infusion
azacitidineDrug
Solution for subcutaneous injection or intravenous infusion
venetoclaxDrug
Tablet for oral administration
INQOVI (oral decitabine)Drug
Tablet for oral administration. HMA = azactidine or decitabine INQOVI = decitabine (oral)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 5 years
- Severity of AEs and SAEsTime frame: 5 years
Locations
24 sites in 15 countries. Site status is shown where the registry gives one.
Oregon Health Sciences University
Portland, Oregon
Huntsman Cancer Institute Univ of Utah
Salt Lake City, Utah
Novartis Investigative Site
Clayton, Victoria, Australia
Novartis Investigative Site
Florianópolis, Santa Catarina, Brazil
Novartis Investigative Site
Vancouver, British Columbia, Canada
Novartis Investigative Site
Tianjin, China
Novartis Investigative Site
Changchun, Jilin, China
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Novartis Investigative Site
Alexandroupoli, Greece
Novartis Investigative Site
Pátrai, Greece
Novartis Investigative Site
Brescia, BS, Italy
Novartis Investigative Site
Florence, FI, Italy
Novartis Investigative Site
Genova, GE, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Fukushima, Japan
Novartis Investigative Site
Kuala Lumpur, Malaysia
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Badalona, Barcelona, Spain
Novartis Investigative Site
Zurich, Switzerland
Novartis Investigative Site
Izmir, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.